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Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell
carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to
ethnicity is not well characterised.
Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose
reductions and outcomes using the International mRCC Database Consortium.
Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of
dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P¼ 0.1197). When adjusted for risk groups,
there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due
to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months,
Po0.0001; 22.6 vs 16.1 months, P¼ 0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P¼ 0.0028; 28.0 vs 18.7 months,
P¼ 0.0069, respectively).
Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with
mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to
longer treatment durations, but direct comparisons are needed.
The treatment of metastatic renal cell carcinoma (mRCC) has been
revolutionised by the introduction of a novel class of therapies
targeting vascular endothelial growth factor (VEGF). These drugs
include sunitinib, sorafenib, bevacizumab, pazopanib, and axitinib,
which have all improved response rates and progression-free
survival (PFS) compared with previous standards of care.
Despite their efficacy, these drugs have toxicities. For example,
the number of patients requiring treatment interruptions, and
dose reductions due to sunitinib toxicities reached 38% and
32%, respectively, in the original phase III registration study
(Motzer et al, 2007). Common and/or serious toxicities associated
with sunitinib include fatigue, hand-foot syndrome, diarrhea,
hypertension, mucositis/stomatitis, hypothyroidism, and cardio-
toxicity (Kollmannsberger et al, 2007; Motzer et al, 2007; Telli et al,
2008). Similarly, dose interruptions and dose reductions, were
required in 21% and 13% of patients on sorafenib, respectively,
and 10% required drug discontinuation because of adverse
events (Escudier et al, 2007). Common toxicities include diarrhea,
skin reaction or rash, fatigue, and hand-foot syndrome (Escudier
et al, 2007).
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Since their widespread use around the world, several reports
have indicated that VEGF-targeted therapy in mRCC may be more
toxic in Asian versus Caucasian populations (Tomita et al, 2010;
Zhou, 2012). In a phase II study of sunitinib in Japanese patients
with mRCC, 78% of patients required dose reduction and 25% of
patients required treatment discontinuation due to treatment-
related adverse events (Tomita et al, 2010). However, comparative
efficacy of these agents with respect to ethnicity is not well
characterised.
Using a large database of patients with mRCC treated
with contemporary targeted therapy, the International mRCC
Database Consortium (IMDC), we sought to determine whether
these differences in toxicities resulted in a difference in the rate of
dose reductions and discontinuation of therapy in patients from
Asian centres when compared with patients from non-Asian
centres and whether PFS and overall survival (OS) is adversely
affected as a result. Secondary analysis included the comparison of
patients who have had dose reductions versus full dose treatment
and their overall treatment duration on the effect of PFS and OS.
METHODS
Study population. Eight centres participating in the IMDC with
available dose reduction and race data on patients with mRCC
treated with VEGF-targeted therapy were included in this analysis.
Patients were identified from consecutive population-based patient
samples from 2005 to 2011 at these centres. Non-Asian patients
were derived from cancer centres in Canada (Alberta Health
Services Cancer Control, British Columbia Cancer Agency) and the
United States (Dana-Farber Cancer Institute, Beth Israel Deaconess
Medical Center). Asian patients were derived from centres in
Korea (Asan Medical Center, Yonsei Cancer Center) and
Singapore (National Cancer Center). Asian patients from non-
Asian centres were excluded (n¼ 8) and non-Asian patients from
Asian centres were excluded (n¼ 3).
Patients may have been treated on clinical trial protocols or off
protocol and may have been treated at major academic centres, or
community oncology centres. Baseline patient characteristics and
outcome data were collected using uniform data collection
templates in this retrospective analysis. Regulatory approval from
local institutional review boards or research ethics boards was
obtained for each centre.
Endpoints. The primary endpoint was OS, which was defined as
the time from drug initiation to the date of death from any cause or
was censored at the last follow-up. Progression-free survival was
defined as the time from drug initiation to the time of disease
progression, or death, or was censored at the last follow-up. We
defined disease progression according to standard Response
Evaluation Criteria in Solid Tumors (RECIST 1.0) (Eisenhauer
et al, 2009).
Statistics (data analysis). Kaplan–Meier curves were constructed
to compare PFS and OS in patients in Asian populations versus
non-Asian populations. Progression-free survival and OS were
also determined for patients in Asian and non-Asian centres
based on whether or not they required dose reductions. It is
assumed that dose reductions are due to clinically significant
toxicities and thus are most important to capture. A dose
reduction is defined as any change in dose to o50mg once daily
for 4 weeks out of a 6-week treatment cycle for sunitinib,
o400mg twice daily for sorafenib, o10mg kg g every 2 weeks
for bevacizumab, and o800mg once daily for pazopanib, and
o5mg twice daily for axitinib.
Chi-squared tests were used to compare percentage values and
continuous variables were compared using the two-sided t-test.
All statistical tests were two-sided, and P-values of o0.05 were
considered significant. Proportional hazards regression was
carried out to adjust the PFS and OS hazard ratio estimates
by IMDC prognostic criteria which stratify patients into
favourable, intermediate, and poor risk groups (Heng et al,
2009). All analyses were carried out on SAS 9.2 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Baseline characteristics. In total, 1024 patients treated with anti-
VEGF therapy with a median follow-up of 29.4 months were
included in this analysis (Table 1). Of those, 464 patients (45%) were
derived from the Asian centres and 560 (55%) from non-Asian
centres. As per IMDC prognostic factors (Heng et al, 2009), the
Asian versus non-Asian patients in favourable, intermediate, and
poor risk categories were 13% vs 22%, 69% vs 50%, and 17% vs 24%,
respectively (Table 1). Among the Asian patients, 84% received
sunitinib, 15% sorafenib, and 1% pazopanib. Among the non-Asian
patients, 73% received sunitinib, 20% sorafenib, and 7% bevacizu-
mab-based treatment. A description of baseline characteristics of
patients from the Asian vs non-Asian population is found in Table 1.
Dose modifications and outcomes. The percentage of dose
modifications/reductions between non-Asians and Asians was
similar (55% vs 61%, P¼ 0.1197) but more patients completely
discontinued treatment due to toxicity in the non-Asian versus the
Asian group (28% vs 21%, P¼ 0.0197) (Table 2). There was no
statistical difference in PFS in Asian vs non-Asian patients (7.2 vs
6.9 months, P¼ 0.0804) (Figure 1). When adjusted for the IDMC
poor prognostic criteria (Heng et al, 2009), there was no difference
in OS (HR 0.887, 95% CI 0.729–1.08, P¼ 0.2322) or PFS (HR
1.069, 95% CI 0.910–1.256, P¼ 0.4184) between non-Asians and
Asians (Table 3).
Interestingly, when patients were dose reduced due to toxicity,
they had a longer treatment duration and OS than those who did
not have toxicity requiring a dose reduction in both the non-Asian
(10.6 vs 5.0 months, Po0.0001, and 22.6 vs 16.1 months,
P¼ 0.0016, respectively) and in the Asian populations (8.9 vs 5.4
months, P¼ 0.0028, and 28.0 vs 18.7 months, P¼ 0.0069) (Figures
2 and 3, Table 4).
Table 1. Comparison of non-Asian population and Asian population
characteristics
Characteristic
Non-Asian
population,
n¼560
Asian
population,
n¼464 P-value
Heng et al risk group
Favourable (%) 22 13
Intermediate (%) 50 69 o0.0001
Poor (%) 24 17
KPS o80% 27 17 o0.0001
Median age (years) 61 58 o0.0001
Gender (% male) 72 72 0.2672
Anaemia (%) 53 70 o0.0001
Thrombocytosis (%) 23 10 o0.0001
Hypercalcemia (%) 11.5 6.7 0.0129
Diagnosis to treatment o1 year (%) 50 58 0.0115
Neutrophilia (%) 14 13 0.7076
Patients with 41 site of metastasis (%) 70 56 o0.0001
Prior nephrectomy (%) 78 81 0.3682
Brain metastases present (%) 9.2 5.4 0.0315
Sarcomatoid histology (%) 4.3 9.5 0.0254
Non-clear cell histology (%) 7.5 15.2 0.0002
Abbreviation: KPS¼Karnofsky Performance Status.
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DISCUSSION AND CONCLUSION
Prior to this analysis, studies demonstrated higher rates of toxicity
in Asian patients compared with historical cohorts in clinical trials
(Naito et al, 2010). For example, the incidence of hand-foot
syndrome (55% in a Japanese study (Akaza et al, 2007) vs 30% in
the initial landmark phase III study (Escudier et al, 2007)) and
hypertension (28% (Akaza et al, 2007) vs 17% (Escudier et al,
2007)) with sorafenib in Japanese patients were higher compared
with those in clinical trial populations that enrolled few Asians.
Similarly, sunitinib demonstrated much more treatment-related
hematologic side effects such as thrombocytopenia (Asian¼ 75%
Kim et al, 2011, non-Asian¼ 7% by Motzer et al, 2007) and
neutropenia (Asian¼ 70.5% by Kim et al, 2011, non-Asian¼ 6%
Motzer et al, 2007) in Asians compared with non-Asians (Hong
et al, 2009; Lee et al, 2009; Naito et al, 2010; Hwang et al, 2010; Yoo
et al, 2010; Zhou, 2012). Comparisons across studies (especially
between population-based cohorts and clinical trials) may lead to
erroneous conclusions as patient population-based cohorts may
encounter higher toxicity rates than clinical trial patients as the
latter may be a healthier population. This analysis uses population-
based data in Asian and non-Asian centres to allow for a more
balanced comparison. One hypothesis that attempts to account for
the difference in adverse effect profiles is a lower median body
surface area (BSA) in Asian populations (Zhou, 2012). Analysis
showed low BSA to be highly predictive of grade 3–4 toxicities
(Odds ratio (OR) 4.2, P¼ 0.02) in 132 patients on sunitinib for
advanced RCC (van der Veldt et al, 2008; Kim et al, 2011). Other
studies have identified single nucleotide polymorphisms (SNPs)
that are associated with toxicity outcomes, suggesting that these are
makers of a linked genetic locus responsible for the difference in
these findings in both individual responses and ethnicities
(Eechoute et al, 2012; Kim et al, 2013; Scartozzi et al, 2013;
Beuselinck et al, 2014). Formal pharmacokinetic analysis of BSA
with ethnic variants in SNPs and adverse effect profiles between
Asian and non-Asian populations would be helpful.
Although studies outline differences in side-effect profiles
between the two populations, no prior study has been conducted
to determine if this results in a difference in OS or PFS as the main
study outcome. This led us to conduct a multicentre retrospective,
population-based analysis of the outcomes in patients who have
Table 2. Comparison of dose reduction and discontinuation rates in
non-Asian population and Asian populations
Non-Asian
population
Asian
population P-value
Percentage of dose
modifications/reductions
55% 61% 0.1197
Discontinued treatment due
to toxicity
28% 21% 0.0197
100
Progression-free survival
P = 0.8038
Non-asian 6.9 months
Asian 7.2 months
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Figure 1. Kaplan–Meier curve of PFS of all patients in Asian vs non-
Asian populations. No difference was observed in PFS between Asians
(red line) and non-Asians (blue line) (P¼0.8038). The full colour version
of this figure is available at British Journal of Cancer online.
Table 3. Hazard ratios for death and progression in non-Asian vs Asian
populations adjusted for Heng et al prognostic criteria
Hazards ratio 95% confidence interval P-value
OS 0.887 0.729–1.08 0.2322
PFS 1.069 0.910–1.256 0.4184
Abbreviations: OS¼overall survival; PFS¼progression-free survival.
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Figure 2. Kaplan–Meier curve of PFS of the Asian population of
patients with dose reduction vs those without dose reduction.
Patients with dose reduction (red line) had significantly longer PFS
compared with patients without dose reduction (blue line) in Asians
(P¼0.0028). The full colour version of this figure is available at
British Journal of Cancer online.
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Figure 3. Kaplan–Meier curve of PFS of the non-Asian population of
patients with dose reduction vs those without dose reduction.
Patients with dose reduction (red line) had significantly longer PFS
compared with patients without dose reduction (blue line) in non-
Asians (Po0.0001). The full colour version of this figure is available at
British Journal of Cancer online.
Table 4. Treatment duration (in months) and OS (in months) in dose
reduced vs non-dosed reduced patients of non-Asian and Asian
populations
Dose
reduced
Non-dose
reduced P-value
Non-Asians
Treatment duration 10.6 5.0 o0.0001
OS 22.6 16.1 0.0016
Asians
Treatment duration 8.9 5.4 0.0028
OS 28.0 18.7 0.0069
Abbreviation: OS¼overall survival.
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been treated with anti-VEGF therapies in Asian and non-Asian
centres. We wondered if differences in toxicity profiles may lead to
a greater frequency of dose reductions or discontinuation of
treatment, thus affecting response rates between the two populations.
Previous studies involving patients treated with both sunitinib
and sorafenib tended towards higher rates of reductions in Asian
populations, within the limitations of small sample sizes and
differences in study populations (Akaza et al, 2007; Gore et al,
2009; Hong et al, 2009; Lee et al, 2009; Zhang et al, 2009; Hwang
et al, 2010; Tomita et al, 2010; Uemura et al, 2010; Yoo et al, 2010;
Kim et al, 2011; Tanigawa et al, 2011; Yang et al, 2012). Contrary
to previous trends, our results showed the percentage of patients
requiring dose modifications/reductions are comparable in the two
groups (55% vs 61% in non-Asian vs Asians, P¼ 0.1197). This
result may reflect increased experience in management of more
contemporary patients and physicians’ cohesive treatment strategies
of side effects regardless of ethnicity. Still, toxicities could be higher in
Asian patients, but at least in our study, these did not contribute to a
higher rate of dose reductions or treatment discontinuation.
Furthermore, in our study, significantly more patients at non-
Asian centres discontinued treatment due to toxicity than did
patients in Asian centres (28% vs 21%, P¼ 0.0197). Interestingly,
the PFS and OS of these two populations did not appear to be
adversely affected by the difference in the rate of treatment
discontinuation. This perhaps points again to variations in SNPs.
Non-Asians who discontinued treatment earlier may have received
as much overall dosing given individual variations in SNPs to gain
equal absolute benefit from treatments regardless of treatment
duration, thus not affecting overall PFS and OS (Kim et al, 2013).
Further studies are needed to elucidate variations in SNPs and
correlation with treatment outcome in our patient population.
Overall, this supports individualised treatment of mRCC with close
follow-up for side effects and dose management.
Our results are consistent with a subanalysis of Asian vs non-
Asian populations in the mRCC expanded-access program (EAP)
for sunitinib (Gore et al, 2009; Lee et al, 2009; Zhou, 2012). The
EAP study enrolled 4564 patients from 52 countries with mRCC
who were ineligible for prior sunitinib clinical trials and received
sunitinib on a compassionate-use basis. In the sub-analysis of 325
Asian vs 4046 non-Asian patients, both populations also showed
similar OS, 18.9 months in Asian patients (95% CI: 15.5–23.5), and
18.4 months in non-Asian patients (95% CI: 17.4–19.2). Despite
the lack of adjustments for prognostic factors, the EAP study did
agree with this current study on OS and PFS between Asian and
non-Asian populations taking sunitinib for mRCC. Although some
toxicities in Asians seem to occur with greater frequency and
severity, this does not seem to result in a difference in response to
treatment between the two populations.
Finally, populations aside, we found that patients who required
dose reductions within each sub-population had an increased
overall treatment duration, and OS (Table 4). The same results
were found in PFS within both populations (Figures 2 and 3).
Similarly, in the original landmark phase III trial comparing
sunitinib vs IFN, the objective response rate to sunitinib treatment
was increased from 37% after a median treatment of 6 months
(95% CI: 26–36) to 47% after 11 months in the updated results
(95% CI: 42–52) (Escudier et al, 2007; Motzer et al, 2009). This
may suggest an ‘area under the curve effect’, where higher exposure
to the medication for longer durations through individualised
dosing strategy, rather than a ‘one dose fits all’ approach, may be
key in conferring a survival advantage (Houk et al, 2010; Ravaud
and Bello, 2011). This could also mean that patients that develop
toxicity and thus require dose reductions have higher drug
exposure than patients who do not require a dose reduction
because they are not experiencing toxicity. This has been
demonstrated in retrospective studies and is currently being
prospectively validated (Bjarnason et al, 2013).
In conclusion, we found that there was no difference in PFS, OS,
and dose reductions required between Asian and non-Asian
populations. Patients who had dose reductions had longer
treatment durations and OS possibly because judicious dose
reductions led to better tolerability and longer courses of
treatment. Additionally, it may also mean that patients who
encounter toxicity requiring dose reductions had higher drug
exposures compared with those who did not encounter toxicity
requiring dose reductions. Further studies that directly and
prospectively test this hypothesis are eagerly anticipated.
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